MSCT与MRI动态增强扫描对高血供肝内胆管癌与肝细胞癌的诊断价值分析

doi:10.3969/j.issn.1672-5069.2020.06.032

摘要/Abstract

摘要： 目的探讨多层螺旋计算机断层扫描(MSCT)与磁共振成像(MRI)动态增强扫描对高血供肝内胆管癌(ICC)和肝细胞癌(HCC)的诊断价值。方法 2018年1月～2019年6月我科诊治的70例原发性肝癌患者,均接受MSCT和MRI动态增强扫描。以手术后组织病理学检查诊断作为金标准,评估两种检查方法的诊断效能。结果经手术后组织病理学检查,在70例原发性肝癌患者中,诊断ICC 12例,HCC 58例;MSCT检查显示HCC病灶动脉期强化、静脉期强化减退,延迟期持续强化减退;MRI多期扫描检查显示39例HCC患者病灶呈快进快出型强化,17例患者病灶呈快进慢出型强化,2例患者病灶呈慢进慢出型强化。MRI多期扫描发现9例ICC患者病灶呈慢进慢出型,3例患者病灶在动脉期和门脉期未出现明显强化,延迟期逐渐呈均匀性强化;MRI诊断HCC患者56例(96.6%),与CT诊断的53例(91.4%)比,无显著性差异(P>0.05),而诊断ICC患者9例(75.0%),显著高于CT诊断的7例(58.3%,P<0.05)。结论在富血供的PLC患者,ICC和HCC的影像学表现有所差异,应用MRI增强扫描有利于提高对ICC的诊断检出率,值得临床积累经验和应用。

关键词: 肝内胆管癌, 肝细胞癌, 多层螺旋计算机断层扫描, 磁共振成像, 诊断

Abstract: Objective The aim of this study was to investigate the clinical application of MSCT and MRI dynamic enhanced scans in diagnosing patients with intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) with high blood supply. Methods A total of 70 patients with primary liver cancer were admitted to our hospital between January 2018 and June 2019, and all underwent MSCT and MRI dynamic enhanced scans. The post-operational histopathological examination was performed as a gold diagnostic criterion. Results The post-operational histopathological examination showed 12 patients with ICC, and 58 patients with HCC in our series; the MSCT multi-phase enhancement demonstrated arterial phase enhancement, venous phase enhancement decline and even enhancement decline in delayed phase in 53 patients with HCC, and arterial phase enhancement, continuous portal phase and delayed phase enhancement in 7 lesions in 12 patients with ICC; the MRI multi-phase enhancement found in 58 patients with HCC having 39 lesions of fast-in and fast-out type enhancement, having 17 lesions of fast-in and slow-out, and having 2 lesions of slow-in and slow-out, and in 12 patients with ICC having 9 lesions of slow-in and slow-out type and having 3 lesions without significant enhancement in arterial and portal phases and with gradually enhancement in delayed phase; the MRI scan made a correct diagnosis of HCC in 56 patients (96.6%), not significantly different compared to in 53 cases (91.4%) by MSCT scan (P>0.05), while it found ICC in 9 patients (75.0%) with ICC, significantly higher than in 7 patients (58.3%) by CT scan (P<0.05). Conclusion There are imaging differences in patients with ICC and HCC with rich blood supply, and the MRI scan might improve diagnosing patients with ICC earlier, which warrants further clinical investigation.

Key words: Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma, Multi-slice spiral computed tomography, Magnetic resonance imaging, Diagnosis

方勇超, 王强, 唐权, 姜帆, 张果, 张玉东. MSCT与MRI动态增强扫描对高血供肝内胆管癌与肝细胞癌的诊断价值分析[J]. 实用肝脏病杂志, 2020, 23(6): 885-888.

Fang Yongchao, Wang Qiang, Tang Quan, et al. Clinicalvalue of MSCT and MRI dynamic enhanced scans in diagnosing patients with intrahepatic cholangiocarcinoma and hepatocellular carcinoma with high blood supply[J]. Journal of Practical Hepatology, 2020, 23(6): 885-888.

参考文献

[1] Sia D, Villanueva A, Friedman SL,et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology, 2017,152(4):745–761.
[2] Orcutt ST, Anaya DA. Liverresection and surgical strategies for management of primary liver cancer. Cancer Control. 2018,25(1):1-15.
[3] Lendoire JC, Gil L, Imventarza O. Intrahepatic cholangiocarcinoma surgery: the impact of lymphadenectomy. Chin Clin Oncol,2018,7(5):53-62.
[4] Hamaoka M, Kozaka K, Matsui O, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol, 2019,37(10):669‐684.
[5] Coskun M. Hepatocellularcarcinoma in the cirrhotic liver: evaluation using computed tomography and magnetic resonance imaging. Exp Clin Transplant, 2017,15(Suppl 2):36‐44.
[6] Nayak A, Baidya Kayal E, Arya M, et al. Computer-aided diagnosis of cirrhosis and hepatocellular carcinoma using multi-phase abdomen CT. Int J Comput Assist Radiol Surg, 2019,14(8):1341‐1352.
[7] Oh J, Lee JM, Park J, et al. Hepatocellularcarcinoma: texture analysis of preoperative computed tomography images can provide markers of tumor grade and disease-free survival. Korean J Radiol, 2019,20(4):569‐579.
[8] Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. Hepatology, 2018,67(1):401‐421.
[9] Horvat N, Monti S, Oliveira BC, et al. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Radiol Oncol, 2018,52(4):353‐364.
[10] Roy R, Dagher A, Butterfield C,et al. ADAM12 is a novel regulator of tumor angiogenesis via STAT3 signaling. Mol Cancer Res, 2017,15(11):1608‐1622.
[11] Krishnapriya S, Malipatil B, Surekha S, et al. Microvesseldensity (MVD) in locally advanced breast cancer. Asian Pac J Cancer Prev, 2019,20(5):1537‐1545.
[12] Oliveira IS, Kilcoyne A, Everett JM,et al. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol (NY), 2017,42(6):1637‐1649.
[13] Ozaki K, Yoshikawa J, Yamamoto T. Morphometric analyses of small accessory liver lobes using radiological imaging. Clin Imaging, 2018,51:43‐49.
[14] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016,150(4):835‐853.
[15] Karaosmanoglu AD, Onur MR, Ozmen MN,et al. Magnetic resonance imaging of liver metastasis. Semin Ultrasound CT MR, 2016,37(6):533‐548.
[16] Min JH, Kim YK, Choi SY, et al. Intrahepaticmass-forming cholangiocarcinoma: Arterial enhancement patterns at MRI and Prognosis. Radiology, 2019,29(3):691–699.
[17] Yano Y, Yoshimatsu K, Yokomizo H,et al. Enhancement of the marginal area in colorectal cancer liver metastasis on computed tomography correlates with microvessel density and clinicopathological factors. Anticancer Res, 2019,39(3):1301‐1308.
[18] Jones RH, Taylor AJ, Rostambeigi N,et al. Small hepatocellular carcinomas displayed as a ring enhancing mass on arterial phase MRI in the chronically diseased liver. Clin Radiol, 2017,72(11):1‐9.
[19] Chiorean L, Caraiani C, Radzi a M,et al. Vascular phases in imaging and their role in focal liver lesions assessment. Clin Hemorheol Microcirc, 2015,62(4):299‐326.
[20] Kim SY, An J, Lim YS, et al. MRIwith liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol, 2017,3(4):456‐463.
[21] Ippolito D, Inchingolo R, Grazioli L, et al. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol, 2018,24(23):2413‐2426.
[22] Joo I, Lee JM, Yoon JH. Imagingdiagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology, 2018,288(1):7‐13.
[23] Fábrega-Foster K, Ghasabeh MA, Pawlik TM,et al. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr, 2017,6(2):67‐78.